A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya
Emily T. O’Neill, Andrew W. Huang, Marta Wilson-Barthes, Imran Manji, Gabriel Kigen, Naftali Busakhala, Samuel Nyanje, Omar Galárraga, Sonak D. Pastakia
Springer Nature ·
2025-06-28
· DOI 10.1007/s40261-025-01454-7
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Emily T. O’Neill, Andrew W. Huang, Marta Wilson-Barthes, Imran Manji, Gabriel Kigen, Naftali Busakhala et al. A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya. // Clinical Drug Investigation. – 2025. – DOI: 10.1007/s40261-025-01454-7. – URL: https://doi.org/10.1007/s40261-025-01454-7
Emily T. O’Neill, Andrew W. Huang, Marta Wilson-Barthes, Imran Manji, Gabriel Kigen, Naftali Busakhala, Samuel Nyanje, Omar Galárraga, & Sonak D. Pastakia (2025). A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01454-7
Emily T. O’Neill, et al. “A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya.” Clinical Drug Investigation, 2025. doi:10.1007/s40261-025-01454-7.
@article{ONeill2025,
title = {A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya},
author = {O’Neill, Emily T. and Huang, Andrew W. and Wilson-Barthes, Marta and Manji, Imran and Kigen, Gabriel and Busakhala, Naftali and Nyanje, Samuel and Galárraga, Omar and Pastakia, Sonak D.},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01454-7},
url = {https://doi.org/10.1007/s40261-025-01454-7}
}